Heart1.com: Great Information, Real Community, Better Living.
 Main Page
 Heart News
Feature Story
 Education Center
 Heart Attack Center
Dr. Tod Engelhardt  Heart

Dr. Tod Engelhardt:
Combating Major Blood Clots.
About Heroes
 Join the Discussion  in  Our Forums
Heart1 Forums
Patient Stories
Online Resources
Video Library
Search the Body1 Network
May 23, 2019  
HEART NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Aspirin Doesn’t Always Help With Heart

    Aspirin Doesn’t Always Help With Heart

    March 27, 2002

    DALLAS (AP) - A new study suggests that some people who take aspirin to ward off heart attacks may not be getting all the benefits they thought they were.

    The study in a recent issue of the journal Circulation found that as many as 75 percent of patients showed some resistance to the blood-thinning effects of aspirin.

    Aspirin works by blocking the formation of thromboxane A2, a chemical in the body that makes platelets sticky and promotes blood clotting. Heart attacks are caused by clots.

    The study found that taking aspirin did not adequately block thromboxane in some people, making them 3 1/2 times more likely to die of a heart attack than those in whom aspirin works.

    Doctors often recommend daily use of aspirin to help prevent heart attacks.

    The study was led by Dr. John Eikelboom, a clinical lecturer at the University of Western Australia, Royal Perth Hospital.

    The researchers analyzed urine samples of 5,529 heart patients in Canada for a chemical byproduct of thromboxane. The levels of the byproduct varied substantially among the aspirin users but were still lower than they were in patients not taking aspirin at all.

    Eikelboom theorized that aspirin did not adequately block thromboxane in some patients because of an underlying genetic mutation.

    The study could be used to identify heart patients who need to be treated with additional anti-clotting medications, said Dr. Salim Yusuf, a co-author of the study. Still, he cautioned, more research is needed.

    Yusuf said a simple urine test could be created to determine if patients are resistant to aspirin.

    Medical experts said those who take aspirin because of heart disease should continue to do so.

    ``We know that aspirin reduces risk of a new cardiac event by as much as 25 percent,' said Dr. Rose Marie Robertson, a professor of medicine at Vanderbilt University in Nashville, Tenn. ``The big message is that not enough people are on aspirin.'


    On the Net:

    American Heart Association: http://www.americanheart.org


    Last updated: 27-Mar-02


  • Add Comment
    Interact on Heart1

    Discuss this topic with others.
    Feature Archives

    Heart Disease Patients Need to Exercise to Benefit from the Protective Effects of Wine

    Effective Treatment for Heart Failure Possible Following Discovery of Heart Molecule

    Significant Decrease in Heart Disease after Prison Smoking Bans

    Heart Failure Patients Who Sleep Poorly Are at Double the Risk for Hospitalization

    Long-Term Survival Possible for Pediatric Heart Transplant Patients

    Next 5 Features ...

    More Features ...
    Related Content
    Docs Slow in Prescribing Better Heart Meds

    Women Seen Undertreated for Heart Disease

    Inflammation Testing Suggested for Millions at Risk of Heart Disease

    Cross Our Hearts and Hope to Live – Better Heart Care for Women

    The American Heart Association Issues New Heart Disease and Stroke Guidelines for Women

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2019 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.